Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Natera
Company facts
- Status
- NASDAQ NTRA
- Headquarters
- AUSTIN, TX
- Industry
- Services-Medical Laboratories SIC 8071
- Fiscal year end
- 1231
- Links
- Filings · SEC · Quote · Yahoo
- Source
- SEC
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −446 | −222 | −310 |
| Net income | −435 | −190 | −208 |
| Total assets | 1,442 | 1,661 | 2,398 |
| Total liabilities | 676 | 465 | 686 |
| Total equity | 765 | 1,195 | 1,712 |
Unit: USD million · Consolidated statements · Source SEC 10-K/20-F
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
Medical testing facility filing citing New England Journal of Medicine paper — Natera, 2025-11-06 · Readout case C131
regulatory filing by a medical testing center citing a Journal of Genetic Counseling paper — Natera, 2023-02-28 · Readout case C077
medical testing facility filing citing Clinical Journal of the American Society of Nephrology paper — Natera, 2021-11-04 · Readout case C054
Medical testing facility filing citing Transplantation paper — Natera, 2022-11-08 · Readout case C069
Journal of Clinical Oncology paper referenced in medical testing company's regulatory filing — Natera, 2024-08-08 · Readout case C106
National R&D projects (NTIS)
No records
Korean patent filings (KIPRIS)
No records
Papers with affiliated authors (OpenAlex)
No records
Last updated 2026-09-21